- Home
- USEA vs NCEL Comparison
USEA vs NCEL Comparison
Compare USEA & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | NCEL |
|---|---|---|
| Founded | 2004 | 2008 |
| Country | Greece | Switzerland |
| Employees | N/A | 4 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 20.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | USEA | NCEL |
|---|---|---|
| Price | $2.34 | $3.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.0K | ★ 70.5K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $1.83 |
| 52 Week High | $2.31 | $5.12 |
Technical Indicators
Market Signals| Indicator | USEA | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | 51.41 |
| Support Level | $1.63 | $2.21 |
| Resistance Level | N/A | $4.38 |
| Average True Range (ATR) | 0.07 | 0.61 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 97.14 | 33.08 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.